<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Inherit Metab Dis</journal-id>
      <journal-title-group>
        <journal-title>Journal of Inherited Metabolic Disease</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0141-8955</issn>
      <issn pub-type="epub">1573-2665</issn>
      <publisher>
        <publisher-name>Springer Netherlands</publisher-name>
        <publisher-loc>Dordrecht</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">20127282</article-id>
      <article-id pub-id-type="pmc">2828550</article-id>
      <article-id pub-id-type="publisher-id">9030</article-id>
      <article-id pub-id-type="doi">10.1007/s10545-009-9030-9</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A potential role for muscle in glucose homeostasis: in vivo kinetic studies in glycogen storage disease type 1a and fructose-1,6-bisphosphatase deficiency</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Huidekoper</surname>
            <given-names>Hidde H.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Visser</surname>
            <given-names>Gepke</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ackermans</surname>
            <given-names>Mari&#xEB;tte T.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sauerwein</surname>
            <given-names>Hans P.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Wijburg</surname>
            <given-names>Frits A.</given-names>
          </name>
          <address>
            <phone>+31-20-5668890</phone>
            <fax>+31-20-6917735</fax>
            <email>f.a.wijburg@amc.uva.nl</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Pediatrics (G8-205) Academic Medical Center, University Hospital of Amsterdam, PO Box&#xA0;22660, NL-1100 DD Amsterdam, The Netherlands </aff>
        <aff id="Aff2"><label>2</label>Department of Clinical Chemistry, Laboratory of Endocrinology, University of Amsterdam, Amsterdam, The Netherlands </aff>
        <aff id="Aff3"><label>3</label>Department of Endocrinology &amp; Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands </aff>
        <aff id="Aff4"><label>4</label>Wilhelmina Children&#x2019;s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands </aff>
      </contrib-group>
      <author-notes>
        <fn fn-type="com">
          <p>Communicated by: Jean-Marie Saudubray</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>2</day>
        <month>2</month>
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>2</day>
        <month>2</month>
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>2</month>
        <year>2010</year>
      </pub-date>
      <volume>33</volume>
      <issue>1</issue>
      <fpage>25</fpage>
      <lpage>31</lpage>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>9</month>
          <year>2009</year>
        </date>
        <date date-type="rev-recd">
          <day>7</day>
          <month>12</month>
          <year>2009</year>
        </date>
        <date date-type="accepted">
          <day>9</day>
          <month>12</month>
          <year>2009</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2010</copyright-statement>
      </permissions>
      <abstract xml:lang="en">
        <sec>
          <title>Background</title>
          <p>A potential role for muscle in glucose homeostasis was recently suggested based on characterization of extrahepatic and extrarenal glucose-6-phosphatase (glucose-6-phosphatase-&#x3B2;). To study the role of extrahepatic tissue in glucose homeostasis during fasting glucose kinetics were studied in two patients with a deficient hepatic and renal glycogenolysis and/or gluconeogenesis.</p>
        </sec>
        <sec>
          <title>Design</title>
          <p>Endogenous glucose production (EGP), glycogenolysis (GGL), and gluconeogenesis (GNG) were quantified with stable isotopes in a patient with glycogen storage disease type 1a (GSD-1a) and a patient with fructose-1,6-bisphosphatase (FBPase) deficiency. The [6,6-<sup>2</sup>H<sub>2</sub>]glucose dilution method in combination with the deuterated water method was used during individualized fasting tests.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>Both patients became hypoglycemic after 2.5 and 14.5 h fasting, respectively. At that time, the patient with GSD-1a had EGP 3.84&#xA0;&#x3BC;mol/kg per min (30% of normal EGP after an overnight fast), GGL 3.09&#xA0;&#x3BC;mol/kg per min, and GNG 0.75&#xA0;&#x3BC;mol/kg per min. The patient with FBPase deficiency had EGP 8.53&#xA0;&#x3BC;mol/kg per min (62% of normal EGP after an overnight fast), GGL 6.89&#xA0;&#x3BC;mol/kg per min GGL, and GNG 1.64&#xA0;&#x3BC;mol/kg per min.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>EGP was severely hampered in both patients, resulting in hypoglycemia. However, despite defective hepatic and renal GNG in both disorders and defective hepatic GGL in GSD-1a, both patients were still able to produce glucose via both pathways. As all necessary enzymes of these pathways have now been functionally detected in muscle, a contribution of muscle to EGP during fasting via both GGL as well as GNG is suggested.</p>
        </sec>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; SSIEM and Springer 2010</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>Endogenous glucose production (EGP) during fasting is predominantly derived from hepatic gluconeogenesis (GNG) and glycogenolysis (GGL), with a minor contribution from renal GNG (Ekberg et al. <xref ref-type="bibr" rid="CR7">1999</xref>). Recently, a potential additional role for muscle in EGP has been suggested based on characterization of an isoform of glucose-6-phosphatase, glucose-6-phosphatase-&#x3B2; (Glc-6-Pase-&#x3B2;) expressed in muscle and other extrahepatic tissue (Martin et al. <xref ref-type="bibr" rid="CR17">2002</xref>; Shieh et al. <xref ref-type="bibr" rid="CR24">2003</xref>). Gl-6-Pase-&#x3B2; has been shown to have structural and functional properties in muscle comparable with glucose-6-phosphatase-&#x3B1; expressed in liver, kidney, and intestine (EC 3.1.3.9; Glc-6-Pase-&#x3B1;) (Shieh et al. <xref ref-type="bibr" rid="CR25">2004</xref>). As patients with glycogen storage disease 1a (GSD-1a; OMIM #232200) are deficient for Glc-6-Pase-&#x3B1;, resulting in defective hepatic and renal GNG and GGL, Gl-6-Pase-&#x3B2; activity in muscle might explain the residual EGP previously observed in these patients (Kalhan et al. <xref ref-type="bibr" rid="CR11">1982</xref>; Schwenk et al. <xref ref-type="bibr" rid="CR23">1986</xref>; Tsalikian et al. <xref ref-type="bibr" rid="CR29">1984</xref>; Weghuber et al. <xref ref-type="bibr" rid="CR30">2007</xref>). In order to investigate the potential role of extrahepatic and extrarenal tissue in glucose homeostasis during fasting in vivo, we performed whole-body kinetic studies in a patient with GSD-1a and a patient with fructose-1,6-bisphosphatase (FBPase) deficiency (OMIM #229700), an inborn error of hepatic and renal GNG. For the first time, differential contributions of GGL and GNG to EGP during fasting were quantified in these disorders using the [6,6-<sup>2</sup>H<sub>2</sub>]glucose isotope dilution method combined with the deuterated water method (Landau et al. <xref ref-type="bibr" rid="CR16">1996</xref>; Wolfe et al. <xref ref-type="bibr" rid="CR31">2005</xref>).</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Materials and methods</title>
      <sec id="Sec3">
        <title>Study individuals</title>
        <p>Patient 1 presented with severe hypoglycemia (plasma glucose 0.3&#xA0;mmol/L) and hepatomegaly at the age of 4&#xA0;months. GSD-1a was diagnosed on the the basis of a complete deficiency of glucose-6-phosphatase activity in a fresh liver biopsy. This diagnosis was later confirmed by mutation analysis revealing two mutations known to completely abolish Glc-6-Pase-&#x3B1; activity (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>) (Rake et al. <xref ref-type="bibr" rid="CR20">2000</xref>). Patient 2 was admitted at 11&#xA0;months because of convulsions due to hypoglycemia. At this time, she exhibited severe metabolic acidosis with hyperlactatemia and a marked hepatomegaly. She was diagnosed with FBPase deficiency by repeated demonstration of undetectable enzyme activity in leucocytes (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>) (Baker et al. <xref ref-type="bibr" rid="CR3">1970</xref>).
<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Sex</th><th>Age (years)</th><th>Height (m)</th><th>Weight (kg)</th><th>Inborn error of metabolism</th><th>Enzyme activity (normal range)</th><th>DNA analysis</th></tr></thead><tbody><tr><td>Patient 1</td><td>M</td><td>17.9</td><td>1.76 (-1 SD)</td><td>75.0 (+1.5 SD)</td><td>Glucose-6-phosphatase deficiency (GSD Ia)</td><td>0.0 (10&#x2013;30) nmol/min/mg protein<sup>a</sup></td><td>R170X &#x2206;F327<sup>b</sup></td></tr><tr><td>Patient 2</td><td>F</td><td>16.7</td><td>1.50 (-2 SD)</td><td>60.0 ( +2 SD)</td><td>Fructose-1,6-bisphosphatase deficiency</td><td>&lt;0.1 (3&#x2013;20) nmol/min/mg protein<sup>c</sup></td><td>ND</td></tr></tbody></table><table-wrap-foot><p><italic>ND</italic> not determined</p><p><sup>a</sup>In hepatocytes</p><p><sup>b</sup>Rake JP et al <xref ref-type="bibr" rid="CR20">2000</xref></p><p><sup>c</sup>In leucocytes, repeated measurements; Baker L et al. <xref ref-type="bibr" rid="CR3">1970</xref></p></table-wrap-foot></table-wrap></p>
        <p>The in vivo stable isotope studies were approved by the Institutional Review Board. Both patients and their parents gave informed consent prior to the studies.</p>
      </sec>
      <sec id="Sec4">
        <title>Study protocol</title>
        <p>Fasting tests were performed at the age of 17.9 and of 16.7&#xA0;years, respectively. Both patients were admitted 1 day before the test. An intravenous catheter was inserted into antecubital veins of both arms after topical application of lidocaine cream. One catheter was used to administer [6,6-<sup>2</sup>H<sub>2</sub>]glucose and the other for blood sampling. At baseline, a blood sample was collected to determine background enrichment of deuterated water in plasma. Fasting was started at a time considered safe based on previous experience with fasting in the patients. Prior to fasting, both patients consumed their regular evening meal. Patient 1 received nocturnal nasogastric drip feeding without glucose polymers. This drip feeding was discontinued 2&#xA0;h prior to initiation of [6,6-<sup>2</sup>H<sub>2</sub>]glucose infusion and substituted by an unlabeled glucose infusion at a rate of 5&#xA0;mg/kg per min, which was continued until the start of the [6,6-<sup>2</sup>H<sub>2</sub>]glucose infusion. Both patients remained fasted throughout the test and maintained bed rest (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Study protocols in patients 1 [glycogen storage disease type 1a (GSD-1a)] and 2 [fructose-1,6-bisphosphatase (FBPase)] deficiency</p></caption><graphic xlink:href="10545_2009_9030_Fig1_HTML" id="MO1"/></fig></p>
        <p>Twelve hours prior to [6,6-<sup>2</sup>H<sub>2</sub>]glucose infusion, both patients drank deuterium-enriched water (99% pure; Cambridge Isotope Laboratories, Cambridge, MA, USA) at a dose of 5&#xA0;g/kg body water divided in five doses within 120 min (Ackermans et al. <xref ref-type="bibr" rid="CR1">2001</xref>). The total amount of body water (kg) was estimated as 60% of body weight (kg) (Friis-Hansen <xref ref-type="bibr" rid="CR8">1961</xref>). Thereafter, patients were only allowed to drink tap water enriched to 0.5% with deuterated water until the end of the test. At the start of the fasting test in patient 1, after 10 h of fasting in patient 2, and after collection of a blood sample to determine background enrichment of [6,6-<sup>2</sup>H<sub>2</sub>]glucose in plasma, a primed continuous infusion of [6,6-<sup>2</sup>H<sub>2</sub>]glucose (99% pure; Cambridge Isotope Laboratories) was started (bolus 26.4&#xA0;&#xB5;mol/kg; continuous infusion 0.33&#xA0;&#xB5;mol/kg per min) to reach an estimated 2% plasma enrichment (Bier et al. <xref ref-type="bibr" rid="CR4">1977</xref>). Blood samples were drawn every 5 min at the beginning and end of the test when patients became hypoglycemic, and every 30 min during the test (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Samples were centrifuged at 3,000&#xA0;rpm for 10&#xA0;min, after which plasma was collected and stored at &#x2013;20&#xB0;C. Blood samples to determine fractional GNG were immediately deproteinized by adding an equal amount of 10% perchloric acid. These samples were centrifuged at 4,000&#xA0;rpm for 20&#xA0;min, after which the supernatant was collected and stored at &#x2013;20&#xB0;C. Blood glucose levels were monitored every hour and more frequently when glucose levels dropped &lt;3.5&#xA0;mmol/L. The test was terminated when clinical symptoms of hypoglycemia occurred, after which patients were immediately given carbohydrate-rich drinks and a meal.</p>
      </sec>
      <sec id="Sec5">
        <title>Analytical methods</title>
        <p><bold>Plasma glucose concentration</bold> Plasma glucose levels were analyzed with the hexokinase method on a Roche MODULAR P800 analyzer (Roche Diagnostics GmbH, Mannheim, Germany).</p>
        <p><bold>Hormones</bold> Plasma insulin and cortisol concentrations were determined on an Immulite 2000 system (Diagnostic Products Corporation, Los Angeles, CA, USA). Insulin was measured with a chemiluminescent immunometric assay, and cortisol was measured with a chemiluminescent immuno assay. Glucagon was determined by RIA (Linco Research, St. Charles, MO, USA). Plasma free fatty acid (FFA) levels were measured by an enzymatic method (NEFAC; Wako Chemicals GmbH, Neuss, Germany).</p>
        <p><bold>Plasma [6,6-<sup>2</sup>H<sub>2</sub>]glucose enrichment</bold> Plasma glucose enrichments were determined as described previously (Ackermans et al. <xref ref-type="bibr" rid="CR1">2001</xref>). Briefly, plasma was deproteinized with methanol and evaporated to dryness. The extract was derivatized with hydroxylamine and acetic anhydride (Reinauer et al. <xref ref-type="bibr" rid="CR21">1990</xref>). The aldonitrile pentaacetate derivative of glucose was extracted into methylene chloride and evaporated to dryness. The extract was reconstituted in ethyl acetate and injected into a gas chromatograph/mass spectrometer (HP 6890 series GC system and 5973 Mass Selective Detector, Agilent Technologies, Palo Alto, CA, USA). Separation was achieved on a J&amp;W DB17 column (30&#xA0;m&#x2009;&#xD7;&#x2009;0.25&#xA0;mm, d<sub><italic>f</italic></sub> 0.25&#xA0;&#xB5;m; J&amp;W Scientific, Folsom, CA). Glucose ions were monitored at <italic>m/z</italic> 187, 188 and 189. The isotopic enrichment of glucose was determined by dividing the peak area of <italic>m/z</italic> 189 by the peak area of <italic>m/z</italic> 187 after correction for background enrichment of [6,6-<sup>2</sup>H<sub>2</sub>]glucose.</p>
        <p><bold>Deuterium enrichment in glucose at position C5 and in plasma water</bold> Glucose was converted to hexamethylene tetra-amine (Ackermans et al. <xref ref-type="bibr" rid="CR1">2001</xref>; Landau et al. <xref ref-type="bibr" rid="CR16">1996</xref>). Hexamethylene tetra-amine was injected into a gas chromatograph/mass spectrometer (HP 6890 series GC system and 5973 Mass Selective Detector, Agilent Technologies). Separation was achieved on an AT-amine column (30&#xA0;m&#x2009;&#xD7;&#x2009;0.25&#xA0;mm, d<sub><italic>f</italic></sub> 0.25&#xA0;&#xB5;m; Alltech Associates Inc, Deerfield, IL, USA). Hexamethylene tetra-amine ions were monitored at <italic>m/z</italic> 140 and 141. Deuterium enrichment in plasma was determined by a method adapted from Previs et al. (Previs et al. <xref ref-type="bibr" rid="CR19">1996</xref>).</p>
      </sec>
      <sec id="Sec6">
        <title>Calculations and statistical analysis</title>
        <p><bold>Rate of glucose appearance</bold> The rate of glucose appearance in plasma (R<sub>a</sub> glucose), reflecting whole-body endogenous glucose production (EGP) during fasting, was calculated with Steele&#x2019;s non-steady-state equation (Steele <xref ref-type="bibr" rid="CR26">1959</xref>). The fraction of the total extracellular glucose pool was assumed to be equal to the extracellular water compartment, which was between 20% and 25% of body weight in the patients studied (Friis-Hansen <xref ref-type="bibr" rid="CR8">1961</xref>). Calculated rates of EGP were compared to rates of EGP after overnight fasting in healthy individuals of the same age, as reported previously (Bier et al. <xref ref-type="bibr" rid="CR4">1977</xref>).</p>
        <p><bold>Absolute gluconeogenesis and glycogenolysis</bold> Absolute GNG was calculated by multiplying R<sub>a</sub> glucose by the fractional GNG. Fractional GNG was calculated as follows (Landau et al. <xref ref-type="bibr" rid="CR16">1996</xref>): 100% &#xB7; (deuterium enrichment in glucose at position C5/deuterium enrichment in plasma water). Absolute GGL was calculated by subtracting absolute GNG from R<sub>a</sub> glucose.</p>
      </sec>
    </sec>
    <sec id="Sec7">
      <title>Results</title>
      <sec id="Sec8">
        <title>Plasma glucose, FFA, and glucoregulatory hormones</title>
        <p><bold>Plasma glucose</bold> In patient 1, after exogenous glucose supplementation was stopped, plasma glucose decreased from 6.3&#xA0;mmol/L to 1.1&#xA0;mmol/L within 2.5&#xA0;h (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). In patient 2, plasma glucose decreased from 3.7&#xA0;mmol/L to 2.5&#xA0;mmol/L at 12&#x2013;14.5&#xA0;h of fasting (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>).
<fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>Glucose kinetics in relation to plasma glucose concentration and fasting duration in a patient with glucose-6-phosphatase deficiency (GSD-1a). Plasma glucose concentrations are depicted in the <italic>left panel</italic> (<bold>A</bold>). Endogenous glucose production (EGP; &#x25CF;), glycogenolysis (GGL; &#x25B2;) and gluconeogenesis (GNG; &#x25BC;) are depicted in the <italic>right panel</italic> (<bold>B</bold>)</p></caption><graphic xlink:href="10545_2009_9030_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig.&#xA0;3</label><caption><p>Glucose kinetics in relation to plasma glucose concentration and fasting duration in a patient with fructose-1,6-bisphosphatase (FBPase) deficiency. Plasma glucose concentrations are depicted in the<italic>left panel</italic> (<bold>A</bold>). Endogenous glucose production (EGP; &#x25CF;), glycogenolysis (GGL; &#x25B2;) and gluconeogenesis (GNG; &#x25BC;) are depicted in the<italic>right panel</italic> (<bold>B</bold>)</p></caption><graphic xlink:href="10545_2009_9030_Fig3_HTML" id="MO3"/></fig></p>
        <p><bold>Plasma FFA</bold> Plasma FFA concentration was 1.64 mmol/L in patient 1 and 2.16&#xA0;mmol/L in patient 2 at the end of the test. This may have been inaccurate in patient 1, as the hypertriglyceridemia could have interfered with the enzymatic assay.</p>
        <p><bold>Glucoregulatory hormones</bold> At the end of the test in both patients, plasma insulin levels were undetectable. Plasma glucagon was 190&#xA0;ng/L in both patients, and plasma cortisol was 666&#xA0;nmol/L in patient 1 and 792&#xA0;nmol/L in patient 2.</p>
      </sec>
      <sec id="Sec9">
        <title>Glucose kinetics</title>
        <p><bold>Patient 1 (GSD-1a)</bold> After 2 h of fasting, EGP was 5.09&#xA0;&#x3BC;mol/kg per min, normal after an overnight fast 13.23&#xA0;&#x3BC;mol/kg per min (Bier et al. <xref ref-type="bibr" rid="CR4">1977</xref>). The test was terminated at 2.6&#xA0;h of fasting (EGP was 3.84&#xA0;&#x3BC;mol/kg per min). GGL decreased from 4.39 to 3.09&#xA0;&#x3BC;mol/kg per min between 2 and 2.6&#xA0;h of fasting, representing 86.2&#x2013;80.5% of EGP, respectively. GNG was low but detectable: 0.60 and 0.78&#xA0;&#x3BC;mol/kg per min (13.7&#x2013;19.6% of EGP) at 2&#x2013;2.6&#xA0;h of fasting (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>).</p>
        <p><bold>Patient 2 (FBPase deficiency)</bold> After 12&#xA0;h of fasting, EGP was 13.27&#xA0;&#x3BC;mol/kg per min, corresponding with the predicted EGP after an overnight fast for this age (13.77&#xA0;&#x3BC;mol/kg per min) (Bier et al. <xref ref-type="bibr" rid="CR4">1977</xref>). EGP decreased to 8.53&#xA0;&#x3BC;mol/kg per min during the subsequent 2.5&#xA0;h (14.5&#xA0;h of fasting). At 12&#xA0;h of fasting, GGL was 10.44&#xA0;&#x3BC;mol/kg per min (78.7% of EGP), decreasing to 6.88&#xA0;&#x3BC;mol/kg per min (80.7% of EGP) during the subsequent 2.5&#xA0;h of fasting. GNG was 2.83&#xA0;&#x3BC;mol/kg per min (21.3% of EGP) at 12&#xA0;h of fasting, decreasing to 1.65&#xA0;&#x3BC;mol/kg per min (19.3% of EGP) during the subsequent 2.5&#xA0;h (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>).</p>
      </sec>
    </sec>
    <sec id="Sec10">
      <title>Discussion</title>
      <p>We report for the first time the contribution of both GGL and GNG to EGP during fasting in a patient with Glc-6-Pase-&#x3B1; deficiency (GSD-1a) and a patient with FBPase deficiency. Our data on glucose kinetics show a persistent EGP from both GGL and GNG in both patients, despite their undetectable enzyme activities. On the basis of these results, a potential role of muscle in glucose homeostasis via both GGL and GNG in vivo is suggested. In patient 1, Glc-6-Pase-&#x3B1; activity was completely deficient, which was confirmed by mutation analysis (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>) (Rake et al. <xref ref-type="bibr" rid="CR20">2000</xref>). This excludes any contribution from liver, kidney, or small intestine to EGP. However, EGP in this patient was still 30% of the predicted EGP in healthy individuals of the same age after an overnight fast (Bier et al. <xref ref-type="bibr" rid="CR4">1977</xref>). This is in line with previous studies showing residual EGP, even up to 60% of normal, in patients with GSD-1 (Kalhan et al. <xref ref-type="bibr" rid="CR11">1982</xref>; Schwenk et al. <xref ref-type="bibr" rid="CR23">1986</xref>; Tsalikian et al. <xref ref-type="bibr" rid="CR29">1984</xref>; Weghuber et al. <xref ref-type="bibr" rid="CR30">2007</xref>).</p>
      <p>Three different explanations for the presence of EGP in GSD-1 have been proposed. First, it has been suggested that EGP is based on increased cycling through hepatic glycogen via action of amylo-1,6-glucosidase. However, this was ruled out by in vivo kinetic stable isotope studies (Rother et al. <xref ref-type="bibr" rid="CR22">1995</xref>). Second, EGP might be due to lysosomal digestion of hepatic glycogen through &#x3B1;-1,4-glucosidase activity. However, this is very unlikely (Kalderon et al. <xref ref-type="bibr" rid="CR9">1989a</xref>; Tsalikian et al. <xref ref-type="bibr" rid="CR29">1984</xref>), as &#x3B1;-1,4-glucosidase is not susceptible to substrate or hormonal regulation, and EGP in patients with GSD-1 is influenced by exogenous glucose supplementation (Schwenk et al. <xref ref-type="bibr" rid="CR23">1986</xref>; Tsalikian et al. <xref ref-type="bibr" rid="CR29">1984</xref>). Third, EGP in GSD-1 may be derived through muscular GGL and/or GNG. This hypothesis was made plausible by recent characterization of muscular Glc-6-Pase-&#x3B2; (Shieh et al. <xref ref-type="bibr" rid="CR24">2003</xref>, <xref ref-type="bibr" rid="CR25">2004</xref>). Although Glc-6-Pase-&#x3B2; has an approximately eightfold lower glucose-6-phosphatase activity than Glc-6-Pase-&#x3B1; (Shieh et al. <xref ref-type="bibr" rid="CR24">2003</xref>), the ubiquitous expression of Glc-6-Pase-&#x3B2; could still result in a significant cumulative glucose-6-phosphatase activity. The observed wide range in residual EGP between GSD-1a patients of the same age and with completely abolished enzyme activity, which is reflected by the interindividual differences in fasting tolerance in patients with GSD-1 (Kalderon et al. <xref ref-type="bibr" rid="CR10">1989b</xref>; Labrune et al. <xref ref-type="bibr" rid="CR14">1993</xref>; Moses <xref ref-type="bibr" rid="CR18">2002</xref>), may then be explained by differences in muscle mass and/or muscular glycogen content.</p>
      <p>In the patient with GSD-1a studied by us, GGL contributed more than 80% to the observed EGP. In addition, GNG still contributed up to 19% to EGP in this patient (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2b</xref>). This contrasts with data from Kalderon et al., who excluded GNG as a source for EGP in GSD-1 based on a lack of carbon recycling from [U-<sup>13</sup>C]glucose (Kalderon et al. <xref ref-type="bibr" rid="CR9">1989a</xref>, <xref ref-type="bibr" rid="CR10">b</xref>). Their method, however, only provides an indirect and nonquantitative assessment of GNG, whereas GNG determined with the deuterated water method, as used in our study, is a direct method to quantify GNG, yielding accurate results (Wolfe et al. <xref ref-type="bibr" rid="CR31">2005</xref>). Possibly, in experiments by Kalderon et al., the <sup>13</sup>C label from [U-<sup>13</sup>C]glucose was diluted beyond detection in the triose phosphate and oxaloacetate carbon pools (Kelleher <xref ref-type="bibr" rid="CR12">1986</xref>). The observed GNG may also be of muscular origin. Apart from Glc-6-Pase-&#x3B2;, a specific isoform of FBPase, another key enzyme in GNG, is functionally expressed in muscle (Tejwani <xref ref-type="bibr" rid="CR27">1983</xref>; Tillmann et al. <xref ref-type="bibr" rid="CR28">1998</xref>). Based on the formerly presumed lack of glucose-6-phosphatase activity in muscle, this muscle-specific FBPase was previously considered not to be involved in GNG (Adams et al. <xref ref-type="bibr" rid="CR2">1990</xref>; Dzugaj <xref ref-type="bibr" rid="CR6">2006</xref>). Alternatively, the observed residual EGP in the patient with GSD-1a might also be explained by renal GGL and/or renal and intestinal GNG, as Glc-6-Pase-&#x3B2; is also expressed in kidney and small intestine (Martin et al. <xref ref-type="bibr" rid="CR17">2002</xref>). However, expression of Glc-6-Pase-&#x3B2; is much lower in kidney and small intestine than in muscle (Martin et al. <xref ref-type="bibr" rid="CR17">2002</xref>) and has yet to been shown to be functionally active in these tissues. Furthermore, muscle has by far the largest body reservoir of glycogen (Shieh et al. <xref ref-type="bibr" rid="CR25">2004</xref>) and is therefore the most likely candidate tissue for extrahepatic and extrarenal glucose production.</p>
      <p>A potential role for muscle in GNG is further supported by results of our study in the patient with liver- and kidney-specific FBPase (EC 3.1.3.11) isoform deficiency. Although liver FBPase activity was not assayed and molecular investigation on the FBPase gene was not performed because, until now, only mixed results on disease-causing mutations have been reported in FBPase deficiency (Kikawa et al. <xref ref-type="bibr" rid="CR13">2002</xref>), the clinical presentation, in combination with repeated confirmation of absent FBPase activity in leucocytes, is highly suggestive of complete absence of liver- and kidney-specific FBPase isoform in patient 2. We detected that GNG still contributed up to 20% to EGP in this patient (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). This might be explained by muscle-specific FBPase isoform activity in combination with Glc-6-Pase-&#x3B2; activity.</p>
      <p>It should be mentioned that a transaldolase exchange reaction may have contributed to deuterium labeling of glucose at position C5 (Landau et al. <xref ref-type="bibr" rid="CR15">1966</xref>). This would lead to an overestimation of gluconeogenesis as calculated from the ratio of deuterium labeling at glucose position C5 over deuterium labeling at glucose position C2. However, this alternative pathway cannot explain the results in the patient with GSD-1a, as functional hepatic glucose-6-phosphatase is still needed to release deuterium-labeled glucose in plasma. In addition, the contribution of this pathway to glucose C5 deuterium labeling in vivo remains to be determined, and therefore, the deuterated water method is currently one of the two best available methods to quantify gluconeogenesis and glycogenolysis in vivo (Bock et al. <xref ref-type="bibr" rid="CR5">2008</xref>).</p>
      <p>Although we report a significant endogenous glucose production from gluconeogenesis and glycogenolysis in a patient with GSD-1a and a patient with FBPase deficiency, it should be noted that EGP in these patients was clearly not sufficient to maintain normoglycemia. Therefore, EGP originating from extrahepatic and extrarenal tissue can play only a minor role in glucose homeostasis in patients with defective hepatic and/or renal glucose production.</p>
      <p>In conclusion, we provide in vivo evidence for both GNG and GGL contributing to EGP in GSD-1a. This, in combination with substantial residual GNG in FBPase deficiency, demonstrates an important role of extrahepatic and extrarenal tissue in glucose homeostasis. Our study strongly suggests a role of muscle in glucose homeostasis via both GGL and GNG.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>We thank Thessa Westphal and Klaske Honig for their technical assistance, and An Ruiter and Barbara Voermans for their excellent analytical support.</p>
      <p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ackermans</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Pereira Arias</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Bisschop</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Endert</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sauerwein</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>Romijn</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>The quantification of gluconeogenesis in healthy men by <sup>2</sup>H<sub>2</sub>O and [2-<sup>13</sup>C]glycerol yields different results: rates of gluconeogenesis in healthy men measured with <sup>2</sup>H<sub>2</sub>O are higher than those measured with [2-<sup>13</sup>C]glycerol</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2001</year>
          <volume>86</volume>
          <fpage>2220</fpage>
          <lpage>2226</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.86.5.2220</pub-id>
          <pub-id pub-id-type="pmid">11344230</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR2">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adams</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Redden</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Menahem</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Characterization of human fructose-1, 6-bisphosphatase in control and deficient tissues</article-title>
          <source>J Inherit Metab Dis</source>
          <year>1990</year>
          <volume>13</volume>
          <fpage>829</fpage>
          <lpage>848</lpage>
          <pub-id pub-id-type="doi">10.1007/BF01800207</pub-id>
          <pub-id pub-id-type="pmid">1964188</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR3">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baker</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Winegrad</surname>
              <given-names>AI</given-names>
            </name>
          </person-group>
          <article-title>Fasting hypoglycaemia and metabolic acidosis associated with deficiency of hepatic fructose-1, 6-diphosphatase activity</article-title>
          <source>Lancet</source>
          <year>1970</year>
          <volume>2</volume>
          <fpage>13</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(70)92474-8</pub-id>
          <pub-id pub-id-type="pmid">4193749</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR4">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bier</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Leake</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Haymond</surname>
              <given-names>MW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Measurement of &#x201C;true&#x201D; glucose production rates in infancy and childhood with 6, 6-dideuteroglucose</article-title>
          <source>Diabetes</source>
          <year>1977</year>
          <volume>26</volume>
          <fpage>1016</fpage>
          <lpage>1023</lpage>
          <pub-id pub-id-type="doi">10.2337/diabetes.26.11.1016</pub-id>
          <pub-id pub-id-type="pmid">913891</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR5">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bock</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schumann</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Basu</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Evidence that processes other than gluconeogenesis may influence the ratio of deuterium on the fifth and third carbons of glucose: implications for the use of <sup>2</sup>H<sub>2</sub>O to measure gluconeogenesis in humans</article-title>
          <source>Diabetes</source>
          <year>2008</year>
          <volume>57</volume>
          <fpage>50</fpage>
          <lpage>55</lpage>
          <pub-id pub-id-type="doi">10.2337/db07-0694</pub-id>
          <pub-id pub-id-type="pmid">17934142</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR6">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dzugaj</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Localization and regulation of muscle fructose-1, 6-bisphosphatase, the key enzyme of glyconeogenesis</article-title>
          <source>Adv Enzyme Regul</source>
          <year>2006</year>
          <volume>46</volume>
          <fpage>51</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="doi">10.1016/j.advenzreg.2006.01.021</pub-id>
          <pub-id pub-id-type="pmid">16857246</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR7">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ekberg</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Landau</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Wajngot</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Contributions by kidney and liver to glucose production in the postabsorptive state and after 60&#xA0;h of fasting</article-title>
          <source>Diabetes</source>
          <year>1999</year>
          <volume>48</volume>
          <fpage>292</fpage>
          <lpage>298</lpage>
          <pub-id pub-id-type="doi">10.2337/diabetes.48.2.292</pub-id>
          <pub-id pub-id-type="pmid">10334304</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR8">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Friis-Hansen</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Body water compartments in children: changes during growth and related changes in body composition</article-title>
          <source>Pediatrics</source>
          <year>1961</year>
          <volume>28</volume>
          <fpage>169</fpage>
          <lpage>181</lpage>
          <pub-id pub-id-type="pmid">13702099</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR9">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalderon</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Korman</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Gutman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lapidot</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Estimation of glucose carbon recycling in children with glycogen storage disease: a <sup>13</sup>C NMR study using [U-<sup>13</sup>C]glucose</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1989</year>
          <volume>86</volume>
          <fpage>4690</fpage>
          <lpage>4694</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.86.12.4690</pub-id>
          <pub-id pub-id-type="pmid">2734314</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR10">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalderon</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Korman</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Gutman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lapidot</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Glucose recycling and production in glycogenosis type I and III: stable isotope technique study</article-title>
          <source>Am J Physiol</source>
          <year>1989</year>
          <volume>257</volume>
          <fpage>E346</fpage>
          <lpage>E353</lpage>
          <pub-id pub-id-type="pmid">2782400</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR11">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalhan</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Gilfillan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tserng</surname>
              <given-names>KY</given-names>
            </name>
            <name>
              <surname>Savin</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Glucose production in type I glycogen storage disease</article-title>
          <source>J Pediatr</source>
          <year>1982</year>
          <volume>101</volume>
          <fpage>159</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="pmid">6953224</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR12">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelleher</surname>
              <given-names>JK</given-names>
            </name>
          </person-group>
          <article-title>Gluconeogenesis from labeled carbon: estimating isotope dilution</article-title>
          <source>Am J Physiol</source>
          <year>1986</year>
          <volume>250</volume>
          <fpage>E296</fpage>
          <lpage>E305</lpage>
          <pub-id pub-id-type="pmid">3953814</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR13">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kikawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Inuzuka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zammarchi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mayumi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Diagnosis of fructose-1, 6-bisphosphatase deficiency using cultured lymphocyte fraction: a secure and noninvasive alternative to liver biopsy</article-title>
          <source>J Inherit Metab Dis</source>
          <year>2002</year>
          <volume>25</volume>
          <fpage>41</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="doi">10.1023/A:1015129616599</pub-id>
          <pub-id pub-id-type="pmid">11999979</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR14">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Labrune</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Chalas</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Baussan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Odievre</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Tolerance to prolonged fasting in two children with type I glycogen storage disease</article-title>
          <source>J Inherit Metab Dis</source>
          <year>1993</year>
          <volume>16</volume>
          <fpage>1044</fpage>
          <lpage>1045</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00711524</pub-id>
          <pub-id pub-id-type="pmid">8127056</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR15">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Landau</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Bartsch</surname>
              <given-names>GE</given-names>
            </name>
          </person-group>
          <article-title>Estimations of pathway contributions to glucose metabolism and the transaldolase reactions</article-title>
          <source>J Biol Chem</source>
          <year>1966</year>
          <volume>241</volume>
          <fpage>741</fpage>
          <lpage>749</lpage>
          <pub-id pub-id-type="pmid">5908138</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR16">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Landau</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Wahren</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chandramouli</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Schumann</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Ekberg</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kalhan</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
          <article-title>Contributions of gluconeogenesis to glucose production in the fasted state</article-title>
          <source>J Clin Invest</source>
          <year>1996</year>
          <volume>98</volume>
          <fpage>378</fpage>
          <lpage>385</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI118803</pub-id>
          <pub-id pub-id-type="pmid">8755648</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR17">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Oeser</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Svitek</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Hunter</surname>
              <given-names>SI</given-names>
            </name>
            <name>
              <surname>Hutton</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>O&#x2019;Brien</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Identification and characterization of a human cDNA and gene encoding a ubiquitously expressed glucose-6-phosphatase catalytic subunit-related protein</article-title>
          <source>J Mol Endocrinol</source>
          <year>2002</year>
          <volume>29</volume>
          <fpage>205</fpage>
          <lpage>222</lpage>
          <pub-id pub-id-type="doi">10.1677/jme.0.0290205</pub-id>
          <pub-id pub-id-type="pmid">12370122</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR18">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moses</surname>
              <given-names>SW</given-names>
            </name>
          </person-group>
          <article-title>Historical highlights and unsolved problems in glycogen storage disease type 1</article-title>
          <source>Eur J Pediatr</source>
          <year>2002</year>
          <volume>161</volume>
          <issue>Suppl 1</issue>
          <fpage>S2</fpage>
          <lpage>S9</lpage>
          <pub-id pub-id-type="pmid">12373565</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR19">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Previs</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Hazey</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Diraison</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Beylot</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Brunengraber</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Assay of the deuterium enrichment of water via acetylene</article-title>
          <source>J Mass Spectrom</source>
          <year>1996</year>
          <volume>31</volume>
          <fpage>639</fpage>
          <lpage>642</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1096-9888(199606)31:6&lt;639::AID-JMS336&gt;3.0.CO;2-S</pub-id>
          <pub-id pub-id-type="pmid">8799297</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR20">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rake</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Berge</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Visser</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Glycogen storage disease type Ia: recent experience with mutation analysis, a summary of mutations reported in the literature and a newly developed diagnostic flow chart</article-title>
          <source>Eur J Pediatr</source>
          <year>2000</year>
          <volume>159</volume>
          <fpage>322</fpage>
          <lpage>330</lpage>
          <pub-id pub-id-type="doi">10.1007/s004310051281</pub-id>
          <pub-id pub-id-type="pmid">10834516</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR21">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reinauer</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gries</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Hubinger</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Knode</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Severing</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Susanto</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Determination of glucose turnover and glucose oxidation rates in man with stable isotope tracers</article-title>
          <source>J Clin Chem Clin Biochem</source>
          <year>1990</year>
          <volume>28</volume>
          <fpage>505</fpage>
          <lpage>511</lpage>
          <pub-id pub-id-type="pmid">2258712</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR22">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rother</surname>
              <given-names>KI</given-names>
            </name>
            <name>
              <surname>Schwenk</surname>
              <given-names>WF</given-names>
            </name>
          </person-group>
          <article-title>Glucose production in glycogen storage disease I is not associated with increased cycling through hepatic glycogen</article-title>
          <source>Am J Physiol</source>
          <year>1995</year>
          <volume>269</volume>
          <fpage>E774</fpage>
          <lpage>E778</lpage>
          <pub-id pub-id-type="pmid">7485494</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR23">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwenk</surname>
              <given-names>WF</given-names>
            </name>
            <name>
              <surname>Haymond</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>Optimal rate of enteral glucose administration in children with glycogen storage disease type I</article-title>
          <source>N Engl J Med</source>
          <year>1986</year>
          <volume>314</volume>
          <fpage>682</fpage>
          <lpage>685</lpage>
          <pub-id pub-id-type="pmid">3081806</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR24">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shieh</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Mansfield</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Chou</surname>
              <given-names>JY</given-names>
            </name>
          </person-group>
          <article-title>A glucose-6-phosphate hydrolase, widely expressed outside the liver, can explain age-dependent resolution of hypoglycemia in glycogen storage disease type Ia</article-title>
          <source>J Biol Chem</source>
          <year>2003</year>
          <volume>278</volume>
          <fpage>47098</fpage>
          <lpage>47103</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M309472200</pub-id>
          <pub-id pub-id-type="pmid">13129915</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR25">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shieh</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Mansfield</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Chou</surname>
              <given-names>JY</given-names>
            </name>
          </person-group>
          <article-title>A potential new role for muscle in blood glucose homeostasis</article-title>
          <source>J Biol Chem</source>
          <year>2004</year>
          <volume>279</volume>
          <fpage>26215</fpage>
          <lpage>26219</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M402036200</pub-id>
          <pub-id pub-id-type="pmid">15087461</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR26">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Steele</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Influences of glucose loading and of injected insulin on hepatic glucose output</article-title>
          <source>Ann N Y Acad Sci</source>
          <year>1959</year>
          <volume>82</volume>
          <fpage>420</fpage>
          <lpage>430</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1749-6632.1959.tb44923.x</pub-id>
          <pub-id pub-id-type="pmid">13833973</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR27">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tejwani</surname>
              <given-names>GA</given-names>
            </name>
          </person-group>
          <article-title>Regulation of fructose-bisphosphatase activity</article-title>
          <source>Adv Enzymol Relat Areas Mol Biol</source>
          <year>1983</year>
          <volume>54</volume>
          <fpage>121</fpage>
          <lpage>194</lpage>
          <pub-id pub-id-type="doi">10.1002/9780470122990.ch3</pub-id>
          <pub-id pub-id-type="pmid">6303063</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR28">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tillmann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Eschrich</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Isolation and characterization of an allelic cDNA for human muscle fructose-1, 6-bisphosphatase</article-title>
          <source>Gene</source>
          <year>1998</year>
          <volume>212</volume>
          <fpage>295</fpage>
          <lpage>304</lpage>
          <pub-id pub-id-type="doi">10.1016/S0378-1119(98)00181-4</pub-id>
          <pub-id pub-id-type="pmid">9678974</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR29">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsalikian</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Simmons</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gerich</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Howard</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Haymond</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>Glucose production and utilization in children with glycogen storage disease type I</article-title>
          <source>Am J Physiol</source>
          <year>1984</year>
          <volume>247</volume>
          <fpage>E513</fpage>
          <lpage>E519</lpage>
          <pub-id pub-id-type="pmid">6388348</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR30">
        <mixed-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Weghuber</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mandl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Krssak</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Characterization of hepatic and brain metabolism in young adults with glycogen storage disease type I</source>
          <year>2007</year>
          <publisher-loc>Am J Physiol Endocrinol Metab</publisher-loc>
          <publisher-name>A magnetic resonance spectroscopy study</publisher-name>
        </mixed-citation>
      </ref>
      <ref id="CR31">
        <mixed-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Wolfe</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Chinkes</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Wolfe</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Chinkes</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
          <article-title>Glucose metabolism</article-title>
          <source>Isotope tracers in metabolic research: principles and practice of kinetic analysis</source>
          <year>2005</year>
          <publisher-loc>Hoboken</publisher-loc>
          <publisher-name>John Wiley &amp; Sons, Inc.</publisher-name>
          <fpage>215</fpage>
          <lpage>257</lpage>
        </mixed-citation>
      </ref>
    </ref-list>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>EGP</term>
          <def>
            <p>Endogenous glucose production</p>
          </def>
        </def-item>
        <def-item>
          <term>GGL</term>
          <def>
            <p>Glycogenolysis</p>
          </def>
        </def-item>
        <def-item>
          <term>GNG</term>
          <def>
            <p>Gluconeogenesis</p>
          </def>
        </def-item>
        <def-item>
          <term>GSD</term>
          <def>
            <p>Glycogen storage disease</p>
          </def>
        </def-item>
        <def-item>
          <term>FBPase</term>
          <def>
            <p>Fructose-1,6-bisphosphatase</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>Competing interest: None declared.</p>
      </fn>
    </fn-group>
  </back>
</article>
</pmc-articleset>
